BGB 23339
Alternative Names: BGB-23339Latest Information Update: 14 Jun 2025
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Anti-inflammatories
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for phase-I development in Inflammation(Monotherapy, In volunteers) in China (PO, Tablet)
- 28 Nov 2024 No recent reports of development identified for phase-I development in Inflammation(Monotherapy, In volunteers) in Australia (PO, Tablet)
- 17 Oct 2022 BeiGene withdraws a phase I clinical trial in healthy volunteers prior to enrolment, as sponsor determined the data was no longer needed (PO, Tablet) (NCT05387668)